Pharmacist Moms Group™
Candace Cotto, RN, and Andrew Skinner, MD, discuss barriers to use of FMTs in managing CDI, highlighting clinician and patient education.
Experts comment on insurance coverage as a factor for the broader use of FMTs for the management of CDI.
Multiple myeloma treatment selection is critical due to the potential for developing treatment resistance over time to the currently prescribed drugs.
With no treatments currently FDA approved, patients arrive at the hospital with no options for treatment beside waiting for the intoxication to pass.
Program Chair Ryan Haumschild, PharmD, MS, MBA, discussed what attendees can look forward to at the inaugural Oncology Pharmacists Connect meeting.
Candace Cotto, RN, reviews the process of incorporating fecal microbiota, live-jslm treatment into clinical practice, what patients can expect, and the room sanitation process after the procedure.
Experts discuss new and emerging treatments the management of CDI, highlighting the phase 3 trials for SER 109.
Women with recurrent urinary tract infections (UTIs) are often on and off antibiotics for years, and even decades, as the only treatment available in health systems for treating UTIs.
Joseph Reilly, BS, PharmD, BCGP, and Andrew Skinner, MD, discuss the potential benefits of using live-jslm early on to treat CDI, as well as the implications of this new treatment.